ClinConnect ClinConnect Logo
Search / Trial NCT01467323

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes

Launched by NOVO NORDISK A/S · Nov 4, 2011

Trial Information

Current as of June 01, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subjects with insulin requiring type 1 or type 2 diabetes for at least 24 months
  • Current treatment with human insulin (either premix of short and long/intermediate acting insulin) in a twice daily treatment regimen preparation and/or self-mix for at least 12 months
  • Body mass index (BMI) below or equal to 35.0 kg/m\^2
  • HbA1c below or equal to 11.0%
  • Exclusion Criteria:
  • Total daily insulin dose at least 1.4 IU/kg
  • Treatment with oral hypoglycaemic agents within the month prior to inclusion
  • Recurrent severe hypoglycaemia (as judged by the investigator)
  • Active proliferative retinopathy
  • Impaired renal function with creatinine at least 150 mcmol/l (1.7 mg/dl)
  • History of pancreatitis

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.

Locations

Ayr, , United Kingdom

Livingstone, , United Kingdom

Watford, , United Kingdom

Graz, , Austria

Berlin, , Germany

Ulm, , Germany

Dublin, , Ireland

Birmingham, , United Kingdom

Kettering, , United Kingdom

Leicester, , United Kingdom

Northampton, , United Kingdom

Nottingham, , United Kingdom

Whiston, , United Kingdom

Bern, , Switzerland

Newcastle, , United Kingdom

Schwedt, , Germany

Bolton, , United Kingdom

Jena, , Germany

Neunkirchen, , Germany

Saarlouis, , Germany

Bath, , United Kingdom

Würzburg, , Germany

Dublin 9, , Ireland

Bristol, , United Kingdom

Hamburg, , Germany

Wien, , Austria

Anklam, , Germany

Cottbus, , Germany

Erkner, , Germany

Leipzig, , Germany

München, , Germany

Quakenbrück, , Germany

Rostock, , Germany

Cork, , Ireland

Blackburn, , United Kingdom

Paisley, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Global Clinical Registry (GCR,1452)

Study Director

Novo Nordisk A/S

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials